Patients suffering from acute coronary syndrome who stop taking
clopidogrel (Plavix) may be more likely to die or to suffer an acute myocardial
infarction especially in the first 90 days after cessation, researchers say.
Plavix, manufactured by
Dr. P. Michael Ho of the
After stopping Plavix, the patients were followed for nearly
seven months. Seventeen percent of them who had only gotten drug treatment and
8 percent of those who had gotten stents died or had a heart attack. Most of
those cases, 60 percent, happened in the first 90 days after stopping Plavix,
regardless of how their initial heart episode was treated.
“We looked at people who took different length of
clopidogrel treatment. We found a twofold increase in risk in the 90-day period
after stopping for those who [took it] less than six months or greater than
nine months. For those who took clopidofrel longer than 12 months or 15 months,
we could not calculate the increased risk because we did not have enough
patients,” Dr. Ho said in the study.
Dr. Ho said that the findings do not offset the benefits of
Plavix use. However, if these results are confirmed by other studies, doctors
may need to see if patients should take Plavix longer, taper off Plavix, or use
other drugs to lower death and heart risk, the researchers wrote.
“The final decision should be left to provider and patient. They
have to weigh the risk of discontinuing clopidogrel against the risk of
abnormal bleeding if it is continued. The clinician needs to weigh the risk and
benefits for each individual patient,” Dr. Ho said.
About 775,000 people have mild heart attacks or chest pain
known as acute coronary syndrome in the
The study, funded by the Quality Enhancement Research
Initiative of the Department of Veterans Affairs, appeared in the February 6
issue of the Journal of the American Medical Association.